Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

Discover Iovance's Q4'24 revenue growth, Proleukin's impact on Amtagvi's future, and how it faces competition like Obsidian's ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Q: Why did my primary care physician tell me that in order to dodge osteoporosis, which my mom and grandmother have, I need ...

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect the brain from the effects of ...